LAUSANNE, Switzerland, 25th January 2016 – Sophia Genetics, the global leader in Data Driven Medicine (DDM), today announced the opening of its research and development wet laboratory at Campus Biotech in Geneva, Switzerland. In this centre of excellence in biotechnology and life science research, Sophia will use this new facility to test its advanced machine learning algorithms against new cases of complex genomic alterations with a broad range of biological samples and across a number of wet lab technologies, complementing the work done in existing R&D facilities in Cambridge (UK) and Lausanne.
To date, 112 health institutions in 20 countries use Sophia DDMTM to accurately and quickly analyse the genetic make-up of thousands of patients worldwide for common cancers and inherited conditions. Developments undertaken at Campus Biotech will directly benefit to the Sophia DDM™ community, an innovative network of pioneering healthcare institutions eager to accelerate the routine clinical use of digital data and Next Generation Sequencing in clinical diagnosis. Sophia DDM™ now acts as a hub for what is to date the world’s largest clinical genomics community for molecular diagnosis.
Speaking about this new milestone for the company, Sophia Genetics CEO and founder Jurgi Camblong explained “Sophia Genetics was founded at the Ecole polytechnique fédérale de Lausanne (EPFL) Innovation Park and I am thrilled that we are now bridging the Swiss Health Valley gap with this new R&D wet lab in Geneva. This high tech facility will ensure we remain at the forefront of our industry globally and we address tomorrow’s needs in routine diagnostics thanks to complex data produced by our experts. They will be used to teach our advanced machine-learning based technologies (Pepper™, Muskat™, and Moka™) to react accurately to even more complex biological problems. Only through innovation will we make the dream of precision medicine a reality for more patients every day.”
A consortium made of the University of Geneva (UNIGE), the Ecole polytechnique fédérale de Lausanne (EPFL), the Bertarelli family and HansJörg Wyss, Campus Biotech is a new centre of excellence in biotechnology and life science research. Located in Geneva, it focuses on pure science and its translation into practical outcomes that have an impact on society and the world.
Benoît Dubuis, Director of the Campus Biotech site commented “We have seen Sophia growing extremely rapidly over the past two years to become a global leader in Data Driven Medicine, and a hub of the world’s largest clinical genomics community. Their corporate history shows that Europe can lead the way in precision medicine and I am proud that they have chosen Campus Biotech to make their passion for innovation at the service of patients.”
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.